Verici Dx plc (AIM:VRCI)

Market Cap	2.73M
Revenue (ttm)	2.67M
Net Income (ttm)	-4.69M
Shares Out	242.54M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	24,742
Average Volume	213,384
Open	1.250
Previous Close	1.125
Day's Range	1.000 - 1.250
52-Week Range	1.000 - 8.500
Beta	1.45
RSI	35.53
Earnings Date	Jul 15, 2025

About Verici Dx

Verici Dx plc develops prognostic and diagnostic tests for kidney transplant patients. Its lead products are Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection. The company is also developing Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Cardiff, the United Kingdom.

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 2020
• Employees: 14
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: VRCI

Financial Performance

In 2024, Verici Dx's revenue was $3.34 million, an increase of 229.62% compared to the previous year's $1.01 million. Losses were -$5.87 million, -32.75% less than in 2023.

Financial numbers in USD